JP2024531234A5 - - Google Patents

Info

Publication number
JP2024531234A5
JP2024531234A5 JP2024508656A JP2024508656A JP2024531234A5 JP 2024531234 A5 JP2024531234 A5 JP 2024531234A5 JP 2024508656 A JP2024508656 A JP 2024508656A JP 2024508656 A JP2024508656 A JP 2024508656A JP 2024531234 A5 JP2024531234 A5 JP 2024531234A5
Authority
JP
Japan
Prior art keywords
cells
modified
primary
hla
islet cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074878 external-priority patent/WO2023019229A1/en
Publication of JP2024531234A publication Critical patent/JP2024531234A/ja
Publication of JP2024531234A5 publication Critical patent/JP2024531234A5/ja
Pending legal-status Critical Current

Links

JP2024508656A 2021-08-11 2022-08-11 同種異系細胞療法のための遺伝子改変された初代細胞 Pending JP2024531234A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163232161P 2021-08-11 2021-08-11
US63/232,161 2021-08-11
US202263297694P 2022-01-07 2022-01-07
US63/297,694 2022-01-07
US202263344502P 2022-05-20 2022-05-20
US63/344,502 2022-05-20
US202263348990P 2022-06-03 2022-06-03
US63/348,990 2022-06-03
US202263353531P 2022-06-17 2022-06-17
US63/353,531 2022-06-17
PCT/US2022/074878 WO2023019229A1 (en) 2021-08-11 2022-08-11 Genetically modified primary cells for allogeneic cell therapy

Publications (2)

Publication Number Publication Date
JP2024531234A JP2024531234A (ja) 2024-08-29
JP2024531234A5 true JP2024531234A5 (https=) 2025-08-18

Family

ID=83692683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508656A Pending JP2024531234A (ja) 2021-08-11 2022-08-11 同種異系細胞療法のための遺伝子改変された初代細胞

Country Status (9)

Country Link
US (1) US20240010988A1 (https=)
EP (1) EP4384189A1 (https=)
JP (1) JP2024531234A (https=)
KR (1) KR20240073006A (https=)
AU (1) AU2022325232A1 (https=)
CA (1) CA3227108A1 (https=)
IL (1) IL310691A (https=)
MX (1) MX2024001208A (https=)
WO (1) WO2023019229A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245598A (zh) * 2021-02-09 2022-12-01 美商千禧製藥公司 用於冷凍及解凍哺乳動物細胞的方法及組成物
AU2024264889A1 (en) * 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2025047921A1 (ja) * 2023-09-01 2025-03-06 株式会社セル―ジョン 拒絶反応に対する回避方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
WO1998011244A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
JP2005500061A (ja) 2001-08-20 2005-01-06 ザ スクリップス リサーチ インスティテュート Ｃｎｎについての亜鉛フィンガー結合ドメイン
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
DE60333487D1 (de) 2002-12-13 2010-09-02 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005232665B2 (en) 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
DK2185192T3 (en) 2007-08-03 2019-02-18 Pasteur Institut LENTIVIRAL TRANSFER VECTORS AND THEIR MEDICAL USES
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
GB201212902D0 (en) 2012-07-20 2012-09-05 Univ Singapore Combinatoric encoding methods for microarrays
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
CA2939411A1 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
US20160017288A1 (en) * 2014-05-28 2016-01-21 Eitan Moshe Akirav Method for inducing the formation of islet structures and improving beta cell function
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AU2016243583B2 (en) 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
US20180291080A1 (en) 2015-09-28 2018-10-11 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
JP2018534264A (ja) 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
CA3025667A1 (en) 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
JP2020505025A (ja) 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
CN110650975B (zh) 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
KR102761791B1 (ko) 2017-06-26 2025-02-05 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
US20210079366A1 (en) 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
EP3728576A4 (en) 2017-12-22 2021-11-24 The Broad Institute, Inc. CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES
CA3109078A1 (en) 2018-07-17 2020-01-23 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells
WO2020018620A1 (en) 2018-07-17 2020-01-23 The Regents Of The University Of California Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
EP4100519A2 (en) 2020-02-05 2022-12-14 The Broad Institute, Inc. Adenine base editors and uses thereof
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CA3193099A1 (en) 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same

Similar Documents

Publication Publication Date Title
Finck et al. Engineered cellular immunotherapies in cancer and beyond
JP7372920B2 (ja) Ｃａｒ ｔ細胞の作製を改良するための方法
JP2024531234A5 (https=)
DE60026166T2 (de) Vetozellen die wirksam in der prävention von transplantatabstossung sind und kein graft-versus-host potential aufweisen
JP7837068B2 (ja) ユニバーサル抗原提示細胞およびその使用
Li et al. Emerging trends in clinical allogeneic CAR cell therapy
JP2018188475A (ja) カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP2024525789A (ja) 細胞ベースの療法のためのポリシストロニックベクター
US20230279352A1 (en) Methods for generating primary immune cells
EP4175651A1 (en) Methods and compositions for editing the b2m locus in b cells
Gea-Banacloche Immunomodulation
CA3249498A1 (en) ALLOGENIC T LYMPHOCYTES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
Su et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
US20210268023A1 (en) Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection
Tatum et al. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors
JP5054875B2 (ja) 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球
Lotz et al. Partial tyrosinase‐specific self tolerance by HLA‐A* 0201‐restricted cytotoxic T lymphocytes in mice and man
Agrawal et al. Vaccine and cell-based therapeutic approaches in acute myeloid leukemia
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
EP3958887B1 (en) Medical uses for inducing or restoring immune tolerance
US20240374722A1 (en) T cell product and use thereof
CN118451181A (zh) 工程化用于基于细胞的疗法的细胞以及相关组合物和方法
WO2026059868A2 (en) Immunosuppression resistant t cells for post-transplant disorders
KR20220095228A (ko) 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
CN117957327A (zh) 用于基于细胞的疗法的多顺反子载体